BioCryst PharmaceuticalsBCRX
BCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 580
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
99% more call options, than puts
Call options by funds: $9.58M | Put options by funds: $4.81M
74% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 23
64% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 67
5% more funds holding
Funds holding: 258 [Q4 2024] → 270 (+12) [Q1 2025]
2.42% more ownership
Funds ownership: 80.95% [Q4 2024] → 83.37% (+2.42%) [Q1 2025]
4% more capital invested
Capital invested by funds: $1.26B [Q4 2024] → $1.31B (+$52.4M) [Q1 2025]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 3 (-2) [Q1 2025]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
26%
upside
Avg. target
$17.13
95%
upside
High target
$30
242%
upside
8 analyst ratings
7 positive
88%
1 neutral
13%
0 negative
0%
B of A Securities Tazeen Ahmad | 71%upside $15 | Buy Maintained | 1 Jul 2025 |
RBC Capital Brian Abrahams | 48%upside $13 | Outperform Reiterated | 30 Jun 2025 |
Wedbush Laura Chico | 105%upside $18 | Outperform Maintained | 30 Jun 2025 |
Needham Serge Belanger | 94%upside $17 | Buy Reiterated | 27 Jun 2025 |
Barclays Gena Wang | 26%upside $11 | Equal-Weight Maintained | 7 May 2025 |
Financial journalist opinion
Based on 10 articles about BCRX published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments.
Positive
Zacks Investment Research
4 days ago
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
4 days ago
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development.
Neutral
GlobeNewsWire
1 week ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 weeks ago
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior 2027 net cash guidance)— RESEARCH TRIANGLE PARK, N.C., June 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has entered into a definitive agreement to sell its European ORLADEYO® (berotralstat) business to Neopharmed Gentili for up to $264 million.
Positive
Zacks Investment Research
2 weeks ago
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Zacks Investment Research
2 weeks ago
5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility
INSW, ASR, BCRX, ASC and RRGB top the list of highly efficient stocks poised for gains amid market volatility.
Positive
Zacks Investment Research
2 weeks ago
New Strong Buy Stocks for June 25th
BILI, AEM, EVR, VEEV and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on June 25, 2025.
Neutral
GlobeNewsWire
3 weeks ago
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
Neutral
GlobeNewsWire
4 weeks ago
ORLADEYO® (berotralstat) Approved in Colombia
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
Charts implemented using Lightweight Charts™